Clinical trial
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent…
NCT00060671 · CTI BioPharma, Industry · Terminated
Key facts
| NCT number | NCT00060671 |
|---|---|
| Title | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma |
| Official title | An Open-Label, Randomized, Phase III Comparative Trial of BBR 2778 + Rituximab Versus Rituximab in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL) |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular, Mixed-Cell, Small Cleaved-Cell, Low-Grade |
| Intervention type | Drug |
| Interventions | rituximab, Pixantrone (BBR 2778) |
| Enrollment | 800 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | May 12, 2003 |
| Last update posted | Jan 19, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: